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Abstract
Mitochondrial (MT) dysfunction is a hallmark of aging and has been associated with most aging-related diseases as well as 
immunological processes. However, little is known about aging, lifestyle and genetic factors influencing mitochondrial DNA 
(mtDNA) abundance. In this study, mtDNA abundance was estimated from the weighted intensities of probes mapping to 
the MT genome in 295,150 participants from the UK Biobank. We found that the abundance of mtDNA was significantly 
elevated in women compared to men, was negatively correlated with advanced age, higher smoking exposure, greater body-
mass index, higher frailty index as well as elevated red and white blood cell count and lower mortality. In addition, several 
biochemistry markers in blood-related to cholesterol metabolism, ion homeostasis and kidney function were found to be 
significantly associated with mtDNA abundance. By performing a genome-wide association study, we identified 50 inde-
pendent regions genome-wide significantly associated with mtDNA abundance which harbour multiple genes involved in the 
immune system, cancer as well as mitochondrial function. Using mixed effects models, we estimated the SNP-heritability of 
mtDNA abundance to be around 8%. To investigate the consequence of altered mtDNA abundance, we performed a phenome-
wide association study and found that mtDNA abundance is involved in risk for leukaemia, hematologic diseases as well as 
hypertension. Thus, estimating mtDNA abundance from genotyping arrays has the potential to provide novel insights into 
age- and disease-relevant processes, particularly those related to immunity and established mitochondrial functions.
Introduction
Mitochondria (MT), in addition to producing energy through 
oxidative processes, are involved in heat production, ion 
storage, apoptosis, intra- and extra-cellular cell signalling, 
biosynthesis and degradation of important metabolites as 
well as the processing of therapeutic agents. Depending on 
the tissue, cells host a dynamic range of multiple mitochon-
dria which in turn contain multiple copies of a tiny circular 
genome (16,569 base pairs). The human mitochondrial pro-
teome consists of more than 1100 proteins, of which only 13 
are encoded in mitochondrial genome (Calvo and Mootha 
2010). In contemporary human populations, several haplo-
groups are defined by ancestral and stable mutations in the 
MT genome. Those haplogroups are derived from adapta-
tion to different geographic areas under distinctive selec-
tion pressure (Torroni et al. 1996) and may also influence 
the abundance of mitochondrial DNA (mtDNA) (Liou et al. 
2010; Gómez-Durán et al. 2012), although there is conflict-
ing evidence (Hulgan et al. 2019; Pyle et al. 2016). Notably, 
different haplogroups have been reported to be associated 
with diseases as well as longevity (Benedictis et al. 1999; 
Chinnery and Gomez-Duran 2018) and as such contribute to 
phenotypic variety within human populations. Mitochondria 
rely on self-replication and are thus prone to cellular stress in 
aging and diseases. Hence, MT dysfunction and a reduction 
in MT biogenesis are hallmarks of aging (López-Otín et al. 
(2013)), and have been associated with most aging-related 
diseases (Haas 2019) as well as immunological processes 
(McGuire 2019).
Indeed, prior reports indicate that the amount of mtDNA 
in the blood decreases with advanced age (McArdle et al. 
2013; Moore et al. 2018) as well as with lifestyle factors such 
as increased smoking behaviour (Cardellach et al. 2003) and 
higher BMI (McArdle et al. 2013). In addition, males were 
reported to have a lower amount of mtDNA in their blood 
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compared to women (Knez et al. 2016), which may be due 
to differing levels of white blood cells (Shim et al. 2020) or 
oestrogen levels (Giordano et al. 2011) between the sexes. 
However, it remains unclear whether the changes in mtDNA 
abundance also related to a reduced number of mitochondria 
in the respective cell population or due to reduced genome 
copies within the mitochondria.
To our knowledge, there is presently no comprehensive 
evaluation of aging or other factors influencing mtDNA 
abundance in nucleated blood cells in a large collection of 
individuals. In addition, few studies have been conducted 
to elucidate the inherited genetic contribution to mtDNA 
abundance (Workalemahu et al. 2017; Guyatt et al. 2019; 
López et al. 2014; Cai et al. 2015; Curran et al. 2007), most 
of which include a low number of individuals. Therefore, 
we aimed to leverage data from the UK Biobank, a cohort 
of more than 500,000 participants aged 40 and above, to 
uncover non-modifiable as well as lifestyle factors associated 
with mtDNA abundance and to further establish a role of 
inherited genetics in shaping the abundance of MT.
Results
We estimated the amount/abundance of mitochondrial DNA 
in blood in 295,150 individuals passing quality control (Sup-
plementary Fig. 1 and Table 1) from the weighted intensities 
of genotyping probes mapped to the MT genome (Supple-
mentary Table S1). We noticed that the individual genotyp-
ing batches (each containing around 5000 individuals) were 
contributing to the variance of the estimated mtDNA abun-
dance (Supplementary Fig. 1). In addition, we found a strong 
effect of genotyping missingness [slope per SD and 95% 
confidence intervals (CI) 0.011 (0.008; 0.015), P < 10–10] 
on the abundance of mitochondrial DNA in UK Biobank 
participants. Hence, we adjusted our analyses by both the 
genotyping batch as well as genotyping missingness.
Association of mitochondrial DNA abundance 
with sex, aging and lifestyle factors
Previous studies implicated a strong role of sex and advanced 
age in mtDNA abundance. Indeed, we found that male sex 
[slope and 95% CI − 0.05 (− 0.057; − 0.043); P < 10–43] and 
advanced age (slope per SD and 95% CI − 0.06 (− 0.064; 
− 0.056); P < 10–238] was strongly associated with mtDNA 
abundance. Since mtDNA abundance may depend on oes-
trogen levels and thus may be influenced by menopausal 
status in women, we next investigated whether menopausal 
status influences mtDNA abundance changes with advanced 
age. To this end, we used a two-lines test to programmati-
cally determine the optimal age cut-off, which found that 
the association of age with mtDNA abundance has differ-
ential effects in women before and after 55 years of age 
(Supplementary Fig. 2). We found that mtDNA abundance 
increases with age in pre-menopausal women and decreases 
in post-menopausal women. In contrast, mtDNA abundance 
decreases steadily in men with advanced age and no differ-
ences between age groups was observed.
Due to the strong effect of sex on mtDNA abundance as 
well as the differential effect of advanced age on mtDNA 
abundance in pre- and post-menopausal women, we present 
all subsequent results separately for males and females. 
In addition to sex and increasing age, we also found that 
more packyears and elevated BMI were negatively associ-
ated with MT DNA abundance in both men and women (Q 
value < 0.05, Fig. 1, Supplementary Table S2). In addition 
to those results, we found that mtDNA abundance is nega-
tively associated with the increased frailty as expressed by 
the frailty index, an accumulation deficit model summariz-
ing self-reported symptoms and diagnoses (Q value < 0.05, 
Fig. 1, Supplementary Table S2). In line with those results, 
individuals with higher mtDNA abundance had a statistically 
significant better/longer survival time after recruitment.
Table 1  Baseline characteristics 
of UK Biobank participants 
by sex
SD standard deviation, IQR interquartile range
a Average mtDNA abundance (mL2RMT) estimated from the weighted genotyping probe intensities (L2R), 
scaled to have a mean of zero and a SD of 1.00 in each genotyping plate
b Median fraction of reported health related deficits out of 49 investigated deficits
Variable UK biobank participants
Females Males Both
Number of individuals 158,762 136,388 295,150
Average age (SD) [years] 56.67 (7.90) 57.14 (8.09) 56.89 (7.99)
Average body mass index (SD) [kg/m2] 27.03 (5.12) 27.83 (4.21) 27.40 (4.74)
Average packyears smoked (SD) 6.40 (12.89) 11.05 (18.85) 8.52 (16.05)
Average mtDNA abundance (SD)a 0.02 (0.99) − 0.03 (0.99) 0.00 (0.99)
Median frailty index (IQR)b 0.11 (0.01–0.21) 0.11 (0.01–0.20) 0.11 (0.01–0.21)
Median call rate (range) 1.00 (0.99–1.00) 1.00 (0.99–1.00) 1.00 (0.99–1.00)
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While we found that the abundance of mtDNA was 
related to the haplogroup of the individuals (Supplementary 
Figure S3), similar and consistent effect sizes were observed 
for the most common haplogroups present in the UKB, indi-
cating that the genetic make-up of the MT itself is not a 
major factor in determining mtDNA abundance changes due 
to age or other factors (Fig. 1, Supplementary Table S2).
Mitochondrial abundance and blood markers
Next, we investigated whether the amount of DNA that is 
hybridized to the genotyping arrays may be directly related 
to the number of nucleated cells per volume of blood. 
Indeed, we found that the white blood cell count was nega-
tively associated with mtDNA abundance (Fig. 1, Supple-
mentary Table S2). However, we also found that increased 
red blood cell count was associated with reduced mtDNA 
abundance, indicating that not only the number of nucle-
ated cells but also other mechanisms seem to play a role 
in governing mtDNA abundance. This conclusion is sup-
ported by the finding that we only observed a weak positive 
correlation of the aggregated autosomal DNA abundance 
with white blood cell count, which was estimated from 
all genotyping probes mapped to autosomes (Fig. 1). We 
also investigated individual blood markers and their asso-
ciation with mtDNA abundance and found that the mtDNA 
abundance was negatively linked to neutrophil, eosinophil, 
basophil and monocyte percentage and positively linked to 
lymphocyte percentage and platelet count (Fig. 2a, Supple-
mentary Table S3). In contrast, autosomal DNA abundance 
was only significantly positively associated with lymphocyte 
percentage in females.
Mitochondrial abundance and biochemistry 
markers
When we investigated the association of 29 biochemistry 
markers (from urine and blood, Fig. 2b, Supplementary 
Table S4) and mtDNA abundance, we noticed significant 
associations with markers related to inflammation (C-reac-
tive protein), kidney function (albumin, cystatin c, urea and 
urate as well as sodium in urine), liver function (alkaline 
phosphatase, alanine aminotransferase), cholesterol metab-
olism (LDL cholesterol, total cholesterol, triglycerides, 
apolipoprotein A) as well as ion homeostasis (calcium and 
phosphate), vitamin D levels and glucose metabolisms (IGF, 
glucose, HbA1c). Since the immune system and thus the 
number of immune cells may well influence the observed 
associations, we also present the analyses adjusted for the 
neutrophil and lymphocyte percentage as well as white blood 
cell count measured in each participant (Fig. 2b, Supple-
mentary Table S4). After adjustment, most of the associated 
markers remained statistically significantly associated with 
mtDNA abundance, albeit with lower effect sizes. Of note, 
markers related to cholesterol metabolisms such as LDL and 
HDL cholesterol, apolipoprotein A and B as well as total 
Fig. 1  Association between 
mitochondrial DNA abundance 
and different covariates. The 
size and colour (see colour 
bar) of the circle represent 
the slope of the association of 
seven features with mitochon-
drial (mL2RMT) as well as 
autosomal DNA abundance 
(mL2R Autosomes), stratified 
by sex (for the precise effect 
sizes see also Supplementary 
Table S2). The associations 
were also analysed separately by 
major MT haplogroup (labelled 
H–X). Correlations which 
were statistically significant 
(Q value < 0.05) are indicated 
with an asterisk. Nominally 
significant associations (P 
value < 0.05) are shown as 
circles with black borders. FI 
frailty index, BMI body mass 
index, mL2RMT median log 2 
ratio of mitochondrial probes; 
survival time, time till death or 
end of follow-up
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cholesterol had even greater effect sizes after adjustment for 
immune cell count. In contrast, we found few associations 
of biochemistry markers with autosomal DNA abundance in 
our analyses. In particular, the only microalbumin in urine 
was found to be negatively associated to autosomal DNA 
abundance in men (Q value < 0.05).
Genetic dissection of mitochondrial abundance
To uncover genetic variants associated with mitochondrial 
abundance, we conducted a genome-wide association study 
(GWAS) in all individuals passing quality control. In total, 
we assessed the association of 3,505,788 variants with 
mtDNA abundance and found 50 regions in the genome 
with genome-wide significant variants (P value < 5 × 10–08, 
Fig. 3). In those regions, a total of 66 independent signals 
were detected at genome-wide significance (Supplemen-
tary Table S5), implicating multiple genes to be involved 
in mtDNA abundance (Fig. 3). Importantly, by positional 
mapping of likely functional variants, we identified genes 
related to the immune system (CXCL6, MEF2C, ITPR3, 
UBE2D1, C7orf73, STIM1, PNP, CRK and SIRPB1), can-
cer and cell cycle (TERT, BAK1, CDK6, CDK10, SUFU, 
FANCI, MDFIC, JMJD1C, USP7, BIK) and mitochondrial 
function (MFN2, TFAM, DGUOK, USP30, CREB5, POLG) 
to be potentially involved in governing mtDNA abundance 
in blood (Fig. 3).
Next, we used fastBAT to investigate the burden of 
mtDNA abundance associated variants within the gene 
bodies of all protein-coding genes. In total, 227 genes 
Fig. 2  Association between mitochondrial DNA abundance and indi-
vidual blood markers. The size and colour of the circle represent the 
slope of the correlation of blood cell counts or other blood measure-
ments (a see also Supplementary Table S3) and biochemistry features 
(b see also Supplementary Table S4) with mitochondrial (mL2RMT) 
as well as autosomal DNA abundance (mL2R Autosomes), stratified 
by sex. In b the association of biochemistry markers with mtDNA 
abundance were additionally adjusted for the neutrophil and lym-
phocyte percentage (% of white blood cells) as well as white blood 
cell count in the last four rows. Correlations which were statistically 
significant (Q value < 0.05) are indicated with an asterisk. Nominally 
significant associations (P value < 0.05) are shown as circles with 
black borders. WBC white blood cells, RBC red blood cells, mL2RMT 
median log 2 ratio of mitochondrial probes, NRBC nucleated red 
blood cells
853Human Genetics (2021) 140:849–861 
1 3
carrying a statistically significant burden were identified (P 
value < 2 × 10–06, Supplementary Table S6). We then inves-
tigated a potential overrepresentation of pathways within 
those genes with WebGestaltR. With this approach, an 
overrepresentation of pathways related to immune activa-
tion, cell–cell adhesion, haematopoiesis, apoptosis, platelet 
production as well as mitochondrial biogenesis and plasma 
lipoprotein assembly was observed (Supplementary Figure 
S4 and Supplementary Table S7).
Finally, we used mixed-effects models to estimate the 
heritability of mtDNA abundance that can be explained by 
the genotyped variants. Accounting for age, sex, genotyping 
missingness, genotyping batch, the first ten genotyping PCs, 
neutrophil and lymphocyte percentage as well as white blood 
cell count, we estimated the SNP-heritability to be 8.3% 
(95% CI 7.6–9.0%), strongly implicating a role of inherited 
genetic variants on mtDNA abundance.
PheWAS of mitochondrial abundance
To estimate the consequence of altered mtDNA abundance 
on disease risk, we performed a Phenome-wide association 
study (PheWAS) on ICD10 codes derived from the hospital 
episode spell data mapped to a total of 1,150 phecodes. We 
found that higher levels of mtDNA abundance were statisti-
cally significantly (Q value < 0.05) associated with increased 
risk for (chronic lymphoid) leukaemia, myeloproliferative 
disease as well as diseases of the spleen (Fig. 4 and Supple-
mentary Table S8). In contrast, higher mtDNA abundance 
resulted in reduced incidence of cardiomegaly, portal hyper-
tension as well as oesophageal bleeding (Fig. 4 and Sup-
plementary Table S8). Finally, prior reports indicated that 
the risk increase due to differences in mtDNA abundance 
may follow a U-shaped distribution (i.e. first and third ter-
tile compared to the second tertile increased the risk for a 
disease) (Workalemahu et al. 2016; Thyagarajan et al. 2012). 
To test this hypothesis, we have repeated the PheWAS to 
compare the lowest or the highest tertile of the mtDNA 
abundance distribution against the second (middle) tertile. 
However, we found that this approach yielded similar results 
as obtained from modelling mtDNA abundance across all 
tertiles. In addition, we observed no additional diseases sta-
tistically significantly associated with mtDNA abundance 
after correction for multiple testing.
Discussion
In this study, we have explored the epidemiological and 
genetic basis of mtDNA abundance in nucleated blood 
cells. We found that age as well as multiple lifestyle and 
health-related factors were associated with the amount of 
mtDNA in blood. In particular, mtDNA abundance seems to 
be mostly influenced by cells involved in the innate immune 
system as well as cholesterol metabolism and ion homeo-
stasis. In addition, our genetic dissection of mtDNA abun-
dance revealed 50 independent GWAS signals as well as 
estimated the heritability of mtDNA abundance to be around 
8%. Finally, we showed that elevated mtDNA abundance is 
associated with risk for incident leukaemia, hypertensive 
disorders and oesophageal bleeding.
Due to the low number of variants and thus probes meas-
uring the abundance of the MT genome, we expected that 
the mtDNA abundance estimates from chip arrays to be 
Fig. 3  Summary of the genome-wide association study of mtDNA 
abundance. Manhattan plot of 3,505,788 variants with minor allele 
frequency greater 5%. Genes influenced by associated variants are 
highlighted in different colours: genes in red harbour exonic variants, 
genes which have associated variants in the intronic region are shown 
in black. In case no intronic or exonic variants are mapped to genes 
in a region, we highlighted the closest gene in green. The red line 
denotes genome-wide significance (P < 5.00 × 10–08) while the blue 
line denotes suggestive evidence for association (P < 1.00 × 10–05). 
The estimated genomic inflation factor λ was 1.147
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noisy. Indeed, we found that our initial (unweighted) mtDNA 
abundance values were not associated with known mtDNA 
correlates such as age, smoking, white blood cell count or 
BMI in a fashion that is consistent with the literature and 
was also negatively correlated to the coverage of the MT 
genome by exome sequencing. Since prior studies suggested 
that normalized exome coverage provides a robust estimate 
of mtDNA abundance and also has higher power to detect 
differences (Zhang et al. 2017; Picardi and Pesole 2012; 
D’Erchia et al. 2015; Longchamps et al. 2020), we, there-
fore, weighted the L2R values of individual array probes 
to more closely resemble the mtDNA abundance estimates 
from exome sequencing. With this approach, we found 
that both estimates are moderately positively correlated 
(R = 0.33) and that the influence of genotype missingness on 
the weighted mtDNA abundance estimate was reduced more 
than tenfold [slope per SD and 95% CI of genotype miss-
ingness correlated to the mL2RMT estimate from MoChA: 
0.146 (0.143; 0.150), P < 10–250]. Since the intensity data 
does not contain any missing values (i.e. the signal inten-
sity gets recorded for all probes), the decreased influence of 
genotyping missingness is unlikely to be attributed to the 
selection of probes with more complete genotyping data. 
Furthermore, the resulting weighted mtDNA abundance esti-
mates were associated with most covariates in a fashion that 
is in line with prior reports while the unweighted estimates 
were not (Supplementary Fig. 5). Thus, while the weighted 
mtDNA abundance estimates may not necessarily be as 
accurate as those determined from qPCR, we can estimate 
mtDNA abundance in the whole UKB cohort, drastically 
increasing our power to detect associations.
Although the effect of genotype missingness on MT 
abundance estimation is strongly reduced with our approach, 
it could still potentially confound our analyses. As such, we 
adjusted our analyses for the call rate to account for those 
differences. Therefore, it is unlikely that the genotyping 
missingness after adjustment would strongly confound most 
of our analyses, particularly since genotyping missingness 
itself was not associated with any of the investigated markers 
in this study (Q values > 0.05, data not shown). To estimate 
the SNP-heritability of mtDNA abundance, the BOLT-LMM 
algorithm computes the relationship between individu-
als from all genotyped variants passing QC. Unless geno-
typing missingness is more strongly pronounced in more 
Fig. 4  Phenome-wide association study of mtDNA abundance. The 
consequence of altered mtDNA abundance on 1150 incident dis-
eases or traits determined from the hospital episode spell data was 
evaluated in all UK Biobank participants (detailed association results 
are presented in Supplementary Table  S8). ICD10 diagnoses were 
mapped to phecodes and the association between discretized mtDNA 
abundance (in tertiles) and the phecodes was estimated with logistic 
regression, adjusted for age at baseline, genotyping batch, total auto-
somal DNA abundance, fraction of neutrophils, fraction of lympho-
cytes, white blood cell count, sex, BMI and smoking at baseline as 
well as the first two principal components of ancestry. Only phecodes 
with more than 250 cases were considered. Statistically significant 
associations (Q value < 0.05) are shown above the red line. Triangles 
facing up indicate increased risk while triangle pointing down indi-
cate reduced risk to due elevated mtDNA abundance
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related individuals, the estimation of relatedness should not 
be majorly confounded, particularly after adjusting for the 
actual genotyping missingness. Our results thus strongly 
implicate that the amount of mitochondrial DNA in nucle-
ated blood cells is heritable. Further genetic studies account-
ing for missingness, DNA quality as well as immune cell 
count are warranted to uncover the precise genetic changes 
responsible for alternations in mtDNA abundance.
The disparities in mtDNA abundance by sex can be attrib-
uted to multiple factors which differ between the sexes. In 
this study, we were particularly interested in the effect of 
oestrogen exposure since it has been hypothesized to influ-
ence mtDNA abundance (Giordano et al. 2011). As such, 
we have investigated whether menopause status plays a role 
in determining mtDNA abundance. Indeed, the amount of 
mtDNA increases in pre-menopausal women with advanced 
age but decreases in post-menopausal women at the same 
rate as observed in males. This observation also explains the 
reduced effect sizes of age observed on the mtDNA abun-
dance in women in the sex-stratified analyses. The program-
matically determined age cut-off is in line with prior stud-
ies which showed that 95% of women are post-menopausal 
at age 55 (Nejat and Chervenak 2010) and using 55 years 
as the cut-off for menopause status should be sufficient in 
most research settings (Phipps et al. 2010). In addition, our 
results may also provide an explanation for the inconsistent 
results observed in the associations of mtDNA abundance 
and breast cancer (Lemnrau et al. 2015; Shen et al. 2015, 
2010; Thyagarajan et al. 2013; Campa et al. 2018), which is 
a largely hormonally driven cancer with a strong influence 
of menopause status on the resulting tumour characteristics 
such as receptor status. Similarly, our results may also have 
implications for the investigation of other diseases which are 
influenced by changes in hormone levels and/or menopause 
status.
Importantly, our results indicate that mtDNA abundance 
is negatively associated with increased age, higher frailty, 
increased smoking behaviour as well as increased BMI, in 
agreement with prior publications. We hypothesized that 
MT copy number may be diminished due to lower rates of 
replication with increasing age (McArdle et al. 2013; Moore 
et al. 2018), due to oxidative stress induced by smoking 
(Cardellach et al. 2003), by low-grade inflammation and 
metabolic stress due to higher BMI (McArdle et al. 2013) 
or due to prior health-related conditions (as expressed by 
the frailty index) (Ashar et al. 2015; Bennett and Molofsky 
2019). Since individuals with a healthier lifestyle tend to 
have higher mtDNA abundance, we also observed a reduced 
incidence of hypertensive disorders such as portal hyperten-
sion and cardiomegaly as well as lower mortality in those 
individuals. In our GWAS, genes related to blood pres-
sure (NLRP6, CREB5 and APOE) were found in regions 
associated with mtDNA abundance, providing a potential 
explanation between increased mtDNA abundance and 
reduced risk for hypertensive diseases. Similarly, pathways 
and genes related to coagulation, platelet production, and 
count were implicated by our GWAS, thus pointing towards 
genes that are involved in both mtDNA abundance and 
risk for oesophageal bleeding. Interestingly, recent reports 
indicated that higher MT abundance is protective against 
oesophageal cancer (Xu et al. 2013), which may indicate that 
the oesophageal tissue is particularly vulnerable to changes 
in mitochondrial DNA abundance.
To further reinforce the notion that mtDNA abundance 
is heritable, we conducted a genome-wide association study 
on over 3 million common variants. We chose to focus on 
common variants since they are less likely to suffer from 
missing genotypes and the imputation of missing alleles is 
more accurate for those variants as well. Our GWAS impli-
cated several genes to be involved in governing mtDNA 
abundance, particularly those related to immunity, cancer, 
cell cycle, and mitochondrial function. This is in line with 
reports that the loss of Y chromosome (mLOY) is related 
to similar pathways (Thompson et al. 2019), although none 
of the genes implicated in this study overlap with the genes 
associated with mLOY. Furthermore, we were able to iden-
tify variants significantly associated with mtDNA abundance 
within a region on chromosome 17 (association signal near 
GSDMA, i.e. genomic locus 40 in Supplementary Table S2), 
which was previously shown to be involved in mtDNA 
abundance [estimated from quantitative PCR (Guyatt et al. 
2019)]. This region was also described to be involved in 
blood cell counts, particularly neutrophils (Astle et al. 2016; 
Okada et al. 2010; Lin et al. 2017). Therefore, our approach 
does seem to accurately capture mtDNA abundance and pro-
vides evidence for additional regions in the genome and thus 
genes involved in mtDNA abundance.
We observed a strong negative association between 
mtDNA abundance and the number of neutrophils and a pos-
itive correlation with lymphocytes percentage. Since neu-
trophils are the most abundant leukocyte and thus the most 
abundant cell carrying DNA, it may seem obvious that the 
amount of DNA hybridized to the array should be positively 
correlated. However, our results rather point to other conclu-
sions. First, we did not observe any association of autosomal 
DNA abundance with the neutrophil count, indicating that 
the total amount of DNA that was hybridized does not play 
a major role, potentially due to careful harmonization of 
DNA concentration used in the genotyping process. Second, 
we observed differential correlation for mtDNA abundance 
with myeloblast-derived and lymphoid immune cells. Since 
both immune cell lineages carry mitochondria, they should 
similarly contribute to increased mtDNA abundance in case 
the measured mtDNA abundance is solely dependent on 
DNA content in blood. Therefore, we conclude that other 
processes must be responsible for the observed association 
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between increased mtDNA abundance and reduced (innate) 
immune cell count.
In our PheWAS analysis, we found increased mtDNA 
abundance to be associated with increased risk of leukae-
mia, which is in agreement with prior findings which found 
higher mtDNA abundance to cause increased leukaemia 
risk (Lan et al. 2008; Kim et al. 2015). Since an increased 
number of circulating lymphocytes is a hallmark of lym-
phoid leukaemia (Kipps et al. 2017) and we found a positive 
association of mtDNA abundance and lymphocyte count, 
this association would seem obvious. However, we adjusted 
our PheWAS by neutrophil and lymphocyte percentage 
as well as white blood cell count, thus the observed effect 
should be largely independent of immune cell abundance. 
Since platelets also contain mitochondria and their count 
can increase acutely through various stimuli (Rokkam and 
Kotagiri 2020), we additionally adjusted the PheWAS analy-
sis by platelet count and found virtually the same results 
(results not shown). Those analyses implicate that other 
mitochondrial mechanisms independent of white blood cell 
count are responsible for the increased risk. Importantly, in 
our GWAS, which was also adjusted for white blood cell 
counts, we found association signals near genes involved 
in leukaemia and lymphoma development (CRK, BAK1, 
CDK6, MDFIC, BIK) as well as a significant enrichment of 
pathways related to immune cell proliferation. Thus, further 
functional studies are necessary to identify the underlying 
mechanism and responsible (immune) cell population that 
links the function of those genes to mtDNA abundance and 
leukaemia.
Of note, the mtDNA estimation was performed at recruit-
ment of the patients and we excluded pre-existing condi-
tions. This allowed us to assess the association of mtDNA 
abundance with diseases in a prospective manner and 
thus our results are unlikely influenced by prevalent dis-
eases, which have been shown to alter mtDNA abundance 
(Ide et al. 2001). The clinical utility if assessing mtDNA 
estimation remains to be evaluated and would face chal-
lenges with our approach: Particularly, the observed effect 
sizes per tertile are in line with a moderate increase in risk 
largely independent of known factors influencing mtDNA 
abundance. Thus, the accuracy to predict the occurrence of 
those diseases would not be great and required additional 
risk factors in a comprehensive model. Therefore, further 
work is necessary to assess the clinical utility of mtDNA 
estimation, particularly while accounting for known risk 
factors for those particular diseases. Nevertheless, mtDNA 
will be a useful marker to add to the increasing number of 
biomarkers reflecting the human aging process, and as such 
will be interesting to study further (Jylhävä et al. 2017).
Multiple blood and urine bound biochemistry markers 
related to cholesterol and triglyceride metabolism as well 
as ion homeostasis and vitamin D levels were found to be 
associated with mtDNA abundance independent of neutro-
phil and lymphocyte percentage or white blood cell count. 
This is in line with prior research (Liu et al. 2005) and the 
proposed function of mitochondria in cells since they are 
instrumental in the metabolism of cholesterol and other 
lipids as well as in ion storage, particularly phosphate and 
calcium.
A recent study presented evidence that cell-free and res-
piratory competent mitochondria are present in blood and 
may have a role in cell–cell communication (Al Amir Dache 
2020). Although the majority of DNA used for the geno-
typing experiments should be derived from nucleated cells, 
our current approach can, however, not distinguish between 
cellular and cell-free mitochondria. It is therefore possi-
ble that some of the observed associations are additionally 
driven by extracellular mitochondria, which warrants further 
investigations.
Conclusion
We show that the amount of mtDNA in nucleated blood 
cells is heritable and associated with different modifiable 
and non-modifiable markers related to aging, health and life-
style as well as immunity, cholesterol metabolism and ion 
homeostasis. Our findings suggest that estimating mtDNA 
abundance from weighted intensities on genotyping arrays is 
a promising tool to gain novel insights into disease-relevant 
mechanisms as well as to study aging.
Methods
UK Biobank study population and DNA extraction
UK Biobank (UKB) is a multi-centre cohort with 502,621 
participants recruited in England, Scotland and Wales. Gen-
otype data were available for 488,279 participants (Sudlow 
et al. 2015). The UK Biobank collected two 10 ml EDTA 
vacutainers per participant and extracted 850 µl of buffy 
coat, which was randomly distributed on extraction plates 
and stored at − 80 °C. The DNA for all participants was 
extracted from the buffy coat aliquot with the Promega 
 Maxwell® 16 Blood DNA Purification Kit (AS1010). In this 
method, DNA is purified using magnetic particles which 
are used to capture, wash and elute DNA. Several quality 
control measures were evaluated after DNA purification and 
only plates that passed this step were used in genotyping 
(Welsh et al. 2017). In addition to the quality control steps 
by the UKB, we had to apply additional exclusion criteria to 
the UK Biobank participants, in line with standard practice 
in genome-wide association studies (Winkler et al. 2014) 
(Supplementary Figure S1). As such, we further excluded 
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individuals with documented and inferred sex chromosome 
abnormalities and those that had a low call rate (less than 
99.0%) or excessive heterozygosity as determined by the 
UKB. Finally, we restricted the analyses to European ances-
try (determined by the genotype principal components) as 
well as unrelated individuals, resulting in a total analytical 
dataset of 295,150 samples (Table 1). Further quality control 
measures based on the genetic dosage/intensity estimation 
are indicated below. The current study was conducted as part 
of the registered project 22,224. The UK Biobank obtained 
broad informed consent from its participants and has been 
approved by IRBs at participating sites. Access to the data 
implies that the proposed analyses are in agreement with the 
relevant IRB approvals.
Variables evaluated
The age and BMI of the individuals were recorded at the 
time of blood draw and smoking status were ascertained 
at baseline interview via questionnaire. The frailty index 
(FI) consisting of 49 health-related items, was computed as 
recently described (Williams et al. 2019) for all participants 
from questionnaire data. Briefly, the Rockwood accumula-
tion deficit model was applied summarizing the number of 
self-reported diseases, symptoms and signs as well as overall 
health assessments in each individual. The FI ranges from 
zero to one and represents the fraction of the actual num-
ber of health deficits reported by an individual divided by 
the total number of potential health deficits considered (i.e. 
queried in the questionnaire). Increased frailty of an indi-
vidual represents a major risk factor for future diseases as 
well as mortality. Recently, the UKB measured a panel of 
29 biomarkers in urine and blood and the data were released 
to the public after extensive quality control. In addition, 
platelet, red and white blood cell counts were measured as 
an absolute number per unit volume and the abundance of 
individual blood cell classes such as lymphocytes, mono-
cytes, neutrophils, eosinophils, basophils were recorded in 
percent (%) of white blood cells. Calibration and quality 
control were performed by the UK Biobank investigators. 
All-cause mortality and thus survival time after recruitment 
was ascertained from the date and cause of death reported up 
until 2018-02-11 for all deceased UK Biobank participants 
(mean follow-up time 8.90 years).
Computation of mitochondrial abundance in UK 
Biobank participants
In the UKB participants, we determined somatic mitochon-
drial DNA abundance [as an approximation of the number of 
mtDNA copies (Longchamps et al. 2020)] from the intensi-
ties of genotyping probes on the MT chromosome. On Affy-
metrix arrays, the relative amount of DNA hybridized to 
the array at each probe is expressed as the log2 ratio (L2R), 
which represents the log2 transformed ratio of the observed 
genotyping probe intensity divided by the intensity at the 
same probe observed in a set of reference samples.
Initially, we computed the median L2R values across all 
265 variants passing quality control on the MT chromosome 
with MoChA (MOsaic Chromosomal Alterations caller) 
(Loh et al. 2020). Similarly, we also computed the median 
L2R value across 12 probes considered to be probes which 
are highly predictive of mtDNA abundance on the Affym-
etrix 6.0 Genome-wide SNP array. This approach is equiva-
lent to the approach used in the MitoPipeline implemented 
in Genvisis (Tin et al. 2016), however only 12 out of the 
25 high-quality probes necessary for the MitoPipeline algo-
rithm are present in the Axiom chips (correlation between 
both estimates R = 0.90).
To compare those array-based estimates to another 
method of mtDNA abundance determination, we also com-
puted the average coverage of the MT genome normalized 
to the total genomic coverage as estimated with mosdepth 
(Pedersen and Quinlan 2018) in around 50,000 individu-
als with whole-exome sequencing (WES) data in the UK 
Biobank (Van Hout et al. 2019). Since no capture probes 
for mtDNA sequences were used for the WES enrichment 
process, this method quantifies the off-target reads that map 
to the MT genome. Prior studies indicated that this approach 
yields accurate mtDNA abundance estimates that are highly 
correlated to qPCR estimates of mtDNA abundance (Zhang 
et al. 2017; Picardi and Pesole 2012; D’Erchia et al. 2015). 
However, we noticed that normalized MT coverage was 
negatively correlated to the mtDNA abundance values ascer-
tained with MoChA (R = − 0.07) or with the MitoPipeline 
approach (R = − 0.06). This finding indicated that several 
poorly performing probes were confounding the abundance 
estimation.
We, therefore, fit a multivariate linear regression model 
to select intensities that are statistically significantly pre-
dicting the normalized MT coverage from exome sequenc-
ing data (Supplementary Table S1). We then multiplied the 
respective L2R value of each probe by the weight in Sup-
plementary Table S1 and computed the median L2R value 
across those weighted L2R values (mL2RMT), resulting in 
a single mtDNA abundance estimate for each individual. 
The distribution was rescaled to have a mean of zero and a 
standard deviation (SD) of one within each genotyping plate 
consisting of 96 samples. The weighted mtDNA abundance 
estimate was positively correlated to the normalized mean 
mitochondrial exome sequencing coverage with a spear-
man rank correlation coefficient of 0.33 (Supplementary 
Fig. 1), indicating that they should capture the same bio-
logical signal, i.e. mtDNA abundance. To assess this and to 
compare our method of mtDNA abundance quantification to 
the (unweighted) approaches, we computed the association 
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of different mtDNA abundance estimates with those estab-
lished variables (Supplementary Fig. 5) such as age (McAr-
dle et al. 2013; Moore et al. 2018), sex (Knez et al. 2016), 
white blood cell count (Shim et al. 2020), smoking (Cardel-
lach et al. 2003) as well as BMI (McArdle et al. 2013). We 
found that the estimates from the weighted computation of 
mtDNA abundance as well as the normalized MT coverage 
accurately reflected mtDNA abundance in agreement with 
prior reports (Supplementary Fig. 5). Importantly, the effect 
sizes large agreed between those approaches, indicating 
that they capture the same biological signal that is mtDNA 
abundance. On the other hand, the unweighted approaches 
yielded contradictory results and therefore do not agree with 
prior findings by other groups, suggesting that they are a 
poor predictor of mtDNA abundance. To further analyse 
potentially haplogroup specific effects, haplogroups in the 
UKB participants were estimated with haplogrep2 (version 
2.1.25) (Weissensteiner et al. 2016) from all MT variants 
genotyped on the chip with standard settings. We only ana-
lysed the top-level haplogroups that were present in more 
than 1000 individuals due to power considerations.
Additional quality control based on the intensity 
and whole‑exome sequencing data in the UKB
Similar to the quality control steps suggested for Illumina 
genotyping arrays, for each individual, we used MoChA to 
compute the standard deviation of the L2R values (SDL2R) 
of all autosomal variants and only included individuals with 
SDL2R of less than 0.36 (i.e. less than two SDs from the 
mean SDL2R of all samples), effectively excluding sam-
ples with excessive variation in their genotyping intensities. 
Furthermore, we excluded individuals with an b-allele fre-
quency phase concordance across phased heterozygous sites 
greater than 0.52 (Vattathil and Scheet 2013). In addition, 
we also computed the average autosomal DNA abundance 
from all autosomal L2R values (mL2Rauto) with MoChA. 
Adjusting for this variable allows us to account for differ-
ences in genotyping quality and differences in DNA hybridi-
zation to the genotyping chip. Furthermore, we compared 
the association results from the mtDNA abundance to the 
overall (autosomal) DNA abundance to identify MT specific 
effects.
Statistical analyses
We coded the continuous mtDNA abundance (mL2RMT) as 
the outcome and used linear regression in R (function lm as 
implemented in base R) to evaluate its correlation with mod-
ifiable (life-style) and non-modifiable exposure variables. In 
the PheWAS, the mtDNA abundance distribution was split 
into tertiles (cut-offs: − 0.43 and 0.39 SD from the mean) 
and considered the exposure for the diseases (i.e. outcome). 
All analyses were adjusted for age at baseline/blood draw, 
sex (determined from the genotyping data), the first two gen-
otype principal components (PCs), the number of missing 
genotypes as well as genotyping batch. We also performed 
some association testing by stratifying patients according 
to their MT haplogroup. Those analyses were additionally 
adjusted by the quality (i.e. confidence) of the respective 
haplotype computation as reported by haplogrep2. To deter-
mine whether mtDNA abundance is correlated to age in a 
U-shaped fashion (i.e. differently between pre- and post-
menopausal women), we computed a two-lines test. This 
approach fits two regression models for women above and 
below a programmatically determined age threshold, respec-
tively, as proposed by Simonsohn (2018). Unless otherwise 
mentioned, to account for multiple testing (where appropri-
ate), we controlled the false-discovery rate to be less than 5% 
and thus report results that have a Q value of less than 0.05.
Genome‑wide association study of mitochondrial 
abundance
The genome-wide association study (GWAS) of mitochon-
drial DNA abundance was computed with plink2 (Chang 
et al. 2015). In general, rare mutations are harder to call 
and usually have more missing genotypes. Since mtDNA 
abundance is associated with missingness, investigating rare 
variants might result in many false-positive findings, which 
are reflective of high missingness. We, therefore, restricted 
the analyses to variants with a minor allele frequency greater 
than 5% as well as those with less than 2% missing data, a 
MACH R2 imputation quality greater than 0.6 as well as not 
deviating significantly (P < 10–05) from Hardy–Weinberg 
equilibrium.
The association between mtDNA abundance and the addi-
tive genotypes in the genome-wide association study was 
adjusted for by the first 10 genotype PCs, age at baseline, 
sex, genotyping batch, genotyping missingness/call rate 
as well as neutrophil percentage, lymphocyte percentage 
and white blood cell count. The genomic inflation factor 
λ was calculated with the GenABEL library version 1.8-0 
implemented in R. We considered variants associated with 
mtDNA abundance with a P value lower than 5 × 10–08 to be 
genome-wide significantly correlated to mtDNA abundance. 
Functional mapping of associated variants to genes within 
genome-wide significant loci was done with FUMA (Watan-
abe et al. 2017). Independent signals within each locus were 
defined as additional association signals at genome-wide sig-
nificance and with a correlation (R2) of less than 0.1 to the 
variant with the lowest P value. In each locus, we consid-
ered the variant (as well as correlated variants at R2 > 0.6) 
within gene bodies with the highest CADD (Rentzsch et al. 
2019) score to be the most likely functional variant and also 
recorded the affected gene (i.e. labelled each locus according 
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to the gene name). Similarly, for variants outside of the gene 
body, we extracted the variant with the lowest RegulomeDB 
(Boyle et al. 2012) score as well as the closest gene to that 
variant.
We used fastBAT implemented in the Complex-Traits 
Genetics Virtual Lab (Cuellar-Partida et al. 2019) using the 
GWAS summary statistics to assess the genetic burden of 
variants associated with mtDNA abundance within the gene 
body of all genes. The statistical significance threshold was 
set at P value < 2.0 × 10−6 which is the Bonferroni correc-
tion threshold for 20,000 protein-coding genes. Genes with 
a statistically significant burden were analysed in a path-
way overrepresentation analysis (ORA) with Webgestalt as 
implemented in WebGestaltR (Liao et al. 2019) in R. Path-
ways for the ORA were retrieved from MSigDB (Liberzon 
et al. 2011) version 7.1 and we report pathways with a size 
of between 25 and 1000 genes and with a Q value of less 
than 0.05.
Heritability estimation of mitochondrial DNA 
abundance
The phenotypic variance explained by additive contributions 
from SNPs (SNP heritability) of mtDNA abundance was 
estimated with the genomic restricted maximum likelihood 
estimation method implemented in the genome-wide com-
plex trait analysis in BOLT-LMM (Loh et al. 2018), with 
standard settings and adjusted for the same covariates as 
described for the genome-wide association analysis.
PheWAS analysis
Diseases were extracted from the hospital episode spell 
data of all individuals passing QC and the ICD10 codes 
were mapped to phecodes (Wu et al. 2019) using the cre-
atePhewasTable function from the PheWAS package (Car-
roll et al. 2014) implemented in R. This approach com-
bines and maps ICD codes from electronic health records 
to clinically relevant outcomes, which were manually 
defined by clinical experts. The hierarchical approach 
also defines related diseases which are built-in exclusion 
criteria to prevent contamination of control individuals 
with cases that have related diseases (Wu et al. 2019). 
We only considered incident diseases, i.e. diseases that 
occurred at least once after blood draw/recruitment. We 
also excluded all patients with prevalent diseases from 
the respective incident data set so only individuals with-
out pre-existing conditions were evaluated within each 
respective phecode or phecode grouping which consists 
of related diseases (Wei et al. 2017). In each association 
analysis, the controls were individuals that did not have 
the respective disease or a related disease at baseline nor 
did they develop the diseases over the follow-up period. 
The PheWAS was performed with the phewas function and 
we only considered phecodes which occurred in more than 
250 cases. In order to reduce the impact of extreme mL2R 
values and to enable comparison with prior studies (Lan 
et al. 2008; Kim et al. 2015), we discretized the variable 
according to tertiles and used this variable as the exposure 
in the PheWAS. The analyses were adjusted for the same 
covariates as the genome-wide association study. Results 
were plotted with the phewasManhattan function.
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